CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy (28% ORR, up to 43% at highest dose) but presents notable GI toxicity risks requiring close monitoring. Financially, CTMX is well-capitalized with $158.1 million in cash, providing a cash runway into late 2027 despite ongoing operating losses.

It isn't difficult for a modestly priced stock to leap in value on a positive news item. That's the dynamic behind the monster rise these past few days of clinical-stage biotech CytomX Therapeutics (CTMX 17.84%).

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Sean McCarthy - Chairman & CEO Conference Call Participants Ross Cohen Presentation Ross Cohen So really quickly on disclosures. So for important disclosures, please see the Morgan Stanley research disclosure website.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 study to address certain recent social media posts.

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.

I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.

CytomX (CTMX) Q2 Revenue Drops 26%

CytomX Therapeutics (CTMX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 7, 2025, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 2:35 p.m. ET.

SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in the ongoing Phase 1 dose escalation study (NCT06462794) evaluating safety and initial clinical activity in patients with metastatic melanoma.

CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by.

CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.